Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
18,514,484
-
Total 13F shares
-
7,863,834
-
Share change
-
+7,385,635
-
Total reported value
-
$18,322,345
-
Price per share
-
$2.33
-
Number of holders
-
32
-
Value change
-
+$17,207,859
-
Number of buys
-
20
-
Number of sells
-
5
Institutional Holders of VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE) as of Q4 2023
As of 31 Dec 2023,
VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE) was held by
32 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
7,863,834 shares.
The largest 10 holders included
Cormorant Asset Management, LP, EVENTIDE ASSET MANAGEMENT, LLC, CITADEL ADVISORS LLC, Soleus Capital Management, L.P., Parkman Healthcare Partners LLC, DSC Advisors, L.P., AlphaCentric Advisors LLC, Palo Alto Investors LP, Exome Asset Management LLC, and PRELUDE CAPITAL MANAGEMENT, LLC.
This page lists
32
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.